{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Spratt DE"],"funding":["NCI NIH HHS"],"pagination":["370-377"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10949135"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["117(2)"],"pubmed_abstract":["Purpose
Intermediate-risk prostate cancer is a heterogeneous disease state with diverse treatment options. The 22-gene Decipher genomic classifier (GC) retrospectively has shown to improve risk stratification in these patients. We assessed the performance of the GC in men with intermediate-risk disease enrolled in NRG Oncology/RTOG 01-26 with updated follow-up.Methods and materials
After National Cancer Institute approval, biopsy slides were collected from NRG Oncology/RTOG 01-26, a randomized phase 3 trial of men with intermediate-risk prostate cancer randomized to 70.2 Gy versus 79.2 Gy of radiation therapy without androgen deprivation therapy. RNA was extracted from the highest-grade tumor foci to generate the locked 22-gene GC model. The primary endpoint for this ancill"],"journal":["International journal of radiation oncology, biology, physics"],"pubmed_title":["Genomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology/RTOG 0126 Randomized Phase 3 Trial."],"pmcid":["PMC10949135"],"funding_grant_id":["R01 CA240991","R21 CA274500","UG1 CA189867","UG1 CA233234","U24 CA196067","U10 CA180868","U10 CA180822","U01 CA257638"],"pubmed_authors":["Robertson JM","Spratt DE","Efstathiou JA","Tran PT","Davicioni E","Michalski J","Thompson DJS","Parliament MB","Dayes IS","Correa RJM","Berlin A","Simko JP","Sandler HM","Liu VYT","Vigneault E","Feng FY","Gore EM","Souhami L","Karrison TG","Hall WA","Doncals DE"],"additional_accession":[]},"is_claimable":false,"name":"Genomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology/RTOG 0126 Randomized Phase 3 Trial.","description":"Purpose
Intermediate-risk prostate cancer is a heterogeneous disease state with diverse treatment options. The 22-gene Decipher genomic classifier (GC) retrospectively has shown to improve risk stratification in these patients. We assessed the performance of the GC in men with intermediate-risk disease enrolled in NRG Oncology/RTOG 01-26 with updated follow-up.Methods and materials
After National Cancer Institute approval, biopsy slides were collected from NRG Oncology/RTOG 01-26, a randomized phase 3 trial of men with intermediate-risk prostate cancer randomized to 70.2 Gy versus 79.2 Gy of radiation therapy without androgen deprivation therapy. RNA was extracted from the highest-grade tumor foci to generate the locked 22-gene GC model. The primary endpoint for this ancill","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Oct","modification":"2026-06-01T13:46:22.967Z","creation":"2025-04-04T13:41:35.863Z"},"accession":"S-EPMC10949135","cross_references":{"pubmed":["37137444"],"doi":["10.1016/j.ijrobp.2023.04.010"]}}